PhaseBio Might Have To Return Global Rights To Its Lead Program
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS ) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition. Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc''s (NASDAQ: AZN ) blood thinner Brilinta (ticagrelor) In January 2020, PhaseBio announced a … Full story available on Benzinga.com
PhaseBio Might Have To Return Global Rights To Its Lead Program
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS ) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition. Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc''s (NASDAQ: AZN ) blood thinner Brilinta (ticagrelor) In January 2020, PhaseBio announced a … Full story available on Benzinga.com